{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:44:56Z","timestamp":1792154696331,"version":"4.4.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clml.2026.09.002","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:24:06Z","timestamp":1788971046000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["IFM 2026 Recommendations for First-line Treatment of Newly Diagnosed Multiple Myeloma"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0131-8689","authenticated-orcid":false,"given":"Aurore","family":"Perrot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7653-711X","authenticated-orcid":false,"given":"Salomon","family":"Manier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Hulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Demarquette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Bobin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6085-2163","authenticated-orcid":false,"given":"Laurent","family":"Frenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Karlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Decaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Arnulf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1580-6106","authenticated-orcid":false,"given":"Jill","family":"Corre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Facon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Touzeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.clml.2026.09.002_bib0001","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","article-title":"EHA\u2013EMN Evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma","volume":"22","author":"Dimopoulos","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"10192","key":"10.1016\/j.clml.2026.09.002_bib0002","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.clml.2026.09.002_bib0003","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"issue":"10218","key":"10.1016\/j.clml.2026.09.002_bib0004","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet"},{"issue":"10068","key":"10.1016\/j.clml.2026.09.002_bib0005","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.clml.2026.09.002_bib0006","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.clml.2026.09.002_bib0007","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clml.2026.09.002_bib0008","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","volume":"31","author":"Usmani","year":"2025","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.clml.2026.09.002_bib0009","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/s41591-024-03050-2","article-title":"Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial","volume":"30","author":"Leleu","year":"2024","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.clml.2026.09.002_bib0010","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1016\/S2352-3026(24)00347-8","article-title":"Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial","volume":"12","author":"Askeland","year":"2025","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1016\/j.clml.2026.09.002_bib0011","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/S1470-2045(25)00280-3","article-title":"Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial","volume":"26","author":"Manier","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2026.09.002_bib0012","unstructured":"A study of bortezomib, lenalidomide and dexamethasone (VRd) followed by Cilta-cel versus VRd followed by lenalidomide and dexamethasone (Rd) in participants with newly diagnosed multiple myeloma for whom ASCT is not planned (CARTITUDE-5). ClinicalTrials.gov identifier: NCT04923893. https:\/\/clinicaltrials.gov\/study\/NCT04923893?term=NCT04923893."},{"key":"10.1016\/j.clml.2026.09.002_bib0013","unstructured":"A study to compare teclistamab in combination with daratumumab and lenalidomide (Tec-DR) versus daratumumab, lenalidomide, and dexamethasone (DRd) in participants with newly diagnosed multiple myeloma (MajesTEC-7). ClinicalTrials.gov. identifier::NCT05552222. https:\/\/clinicaltrials.gov\/study\/NCT05552222?term=NCT05552222."},{"key":"10.1016\/j.clml.2026.09.002_bib0014","unstructured":"A study of elranatamab, daratumumab, and lenalidomide versus daratumumab, lenalidomide, and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma (MagnetisMM-6). ClinicalTrials.gov. identifier::NCT05623020. https:\/\/clinicaltrials.gov\/study\/NCT05623020?term=NCT05623020."},{"key":"10.1016\/j.clml.2026.09.002_bib0015","unstructured":"A study evaluating etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in frailer transplant-ineligible patients with newly diagnosed multiple myeloma (ENTRUST). ClinicalTrials.gov. identifier::NCT07095452. https:\/\/clinicaltrials.gov\/study\/NCT07095452?term=NCT07095452."},{"issue":"4","key":"10.1016\/j.clml.2026.09.002_bib0016","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clml.2026.09.002_bib0017","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1200\/JCO-24-02266","article-title":"Isatuximab, lenalidomide, bortezomib, and dexamethasone induction therapy for transplant-eligible newly diagnosed multiple myeloma: final part 1 analysis of the GMMG-HD7 trial","volume":"43","author":"Mai","year":"2025","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clml.2026.09.002_bib0018","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.clml.2026.09.002_bib0019","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1200\/JCO-24-01893","article-title":"International Myeloma Society\/International Myeloma Working Group Consensus recommendations on the definition of high-risk multiple myeloma","volume":"43","author":"Avet-Loiseau","year":"2025","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2026.09.002_bib0020","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1182\/blood.2025029999","article-title":"High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing","volume":"147","author":"Schavgoulidze","year":"2026","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.09.002_bib0021","unstructured":"A study comparing daratumumab, bortezomib, lenalidomide and dexamethasone followed by ciltacabtagene autoleucel versus daratumumab, bortezomib, lenalidomide and dexamethasone followed by autologous stem cell transplant in participants with newly diagnosed multiple myeloma (EMagine\/CARTITUDE-6; EMN28). ClinicalTrials.gov identifier: NCT05257083. https:\/\/clinicaltrials.gov\/study\/NCT05257083?term=NCT05257083."},{"key":"10.1016\/j.clml.2026.09.002_bib0022","unstructured":"A study evaluating elranatamab in consolidation\/maintenance after induction \u00b1 autologous stem cell transplant in newly diagnosed multiple myeloma (ELLEN; IFM 2025-01). ClinicalTrials.Gov identifier: NCT06918002. https:\/\/clinicaltrials.gov\/study\/NCT06918002?term=NCT06918002."},{"key":"10.1016\/j.clml.2026.09.002_bib0023","unstructured":"A phase III multicenter study to evaluate consolidation treatment with AZD0120 compared with ASCT, in participants with newly diagnosed multiple myeloma who are transplant eligible (DURGA-6). ClinicalTrials.gov identifier: NCT07735637. https:\/\/clinicaltrials.gov\/study\/NCT07735637?term=NCT07735637."},{"key":"10.1016\/j.clml.2026.09.002_bib0024","unstructured":"A study of Teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy following autologous stem cell transplantation in participants with newly diagnosed multiple myeloma (MajesTEC-4\/EMN30). ClinicalTrials.gov. identifier::NCT05243797. https:\/\/clinicaltrials.gov\/study\/NCT05243797?term=NCT05243797."},{"key":"10.1016\/j.clml.2026.09.002_bib0025","unstructured":"An open-label, multicenter, randomized phase 3 study of elranatamab versus lenalidomide in posttransplant patients with newly diagnosed multiple myeloma (MagnetisMM-7). ClinicalTrials.gov. identifier::NCT05317416. https:\/\/clinicaltrials.gov\/study\/NCT05317416?term=NCT05317416."},{"key":"10.1016\/j.clml.2026.09.002_bib0026","unstructured":"Comparison of elranatamab and lenalidomide versus daratumumab and lenalidomide as post-transplant maintenance therapy in patients with newly diagnosed myeloma (ELMMA; IFM 2024-06). ClinicalTrials.gov identifier: NCT06931704. https:\/\/clinicaltrials.gov\/study\/NCT06931704?term=NCT06931704."},{"issue":"1","key":"10.1016\/j.clml.2026.09.002_bib0027","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood.2024026230","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial","volume":"146","author":"Perrot","year":"2025","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2026.09.002_bib0028","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1038\/s41591-026-04282-0","article-title":"Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial","volume":"32","author":"Gay","year":"2026","journal-title":"Nat Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502603288X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502603288X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T11:49:33Z","timestamp":1792151373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502603288X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":28,"alternative-id":["S215226502603288X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.09.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IFM 2026 Recommendations for First-line Treatment of Newly Diagnosed Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}